Page last updated: 2024-08-24

fluorodeoxyglucose f18 and cediranib

fluorodeoxyglucose f18 has been researched along with cediranib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bokacheva, L; Carlin, S; Halliday, J; Kotedia, K; Koutcher, JA; Le, CH; Reese, M; Ricketts, SA	1
Barquin, E; Collins, B; Gardner, K; Judson, I; Jürgensmeier, JM; Leahy, M; Marotti, M; Scurr, M; Young, H	1

Trials

2 trial(s) available for fluorodeoxyglucose f18 and cediranib

Article	Year
Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI. NMR in biomedicine, 2013, Volume: 26, Issue:2 Topics: Animals; Antineoplastic Agents; Contrast Media; Fluorodeoxyglucose F18; Gadolinium DTPA; HT29 Cells; Humans; Neoplasms, Experimental; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Rats; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Xenograft Model Antitumor Assays	2013
Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jul-01, Volume: 20, Issue:13 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Sarcoma; Tomography, X-Ray Computed; Treatment Outcome	2014

Article

Year

Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.

NMR in biomedicine, 2013, Volume: 26, Issue:2

Topics: Animals; Antineoplastic Agents; Contrast Media; Fluorodeoxyglucose F18; Gadolinium DTPA; HT29 Cells; Humans; Neoplasms, Experimental; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Rats; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Xenograft Model Antitumor Assays

2013

Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jul-01, Volume: 20, Issue:13

Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Sarcoma; Tomography, X-Ray Computed; Treatment Outcome

2014